| | MF (n = 207) | PV (n = 380) | ET (n = 226) |
|---|
Symptom | Mean Score | Incidence, % | Mean Score | Incidence, % | Mean Score | Incidence, % |
|---|
Fatigueb
| 5.1 | 80 | 4.6 | 73 | 4.3 | 71 |
Abdominal discomfort | 2.3 | 53 | 1.4 | 35 | 1.3 | 31 |
Night sweatsc
| 2.3 | 51 | 2.0 | 45 | 1.9 | 38 |
Early satiety | 2.0 | 37 | 1.1 | 22 | 1.0 | 21 |
Bone paind
| 2.0 | 40 | 1.2 | 23 | 1.2 | 27 |
Inactivity | 1.9 | 31 | 1.5 | 24 | 1.0 | 19 |
Itching | 1.8 | 40 | 2.9 | 55 | 1.4 | 33 |
Weight loss | 1.6 | 28 | 0.5 | 12 | 0.5 | 10 |
Concentration problems | 1.5 | 29 | 2.0 | 36 | 1.9 | 35 |
Fever | 0.6 | 14 | 0.2 | 5 | 0.2 | 6 |
MPN-SAF TSS | 21.2 | NA | 17.4 | NA | 14.8 | NA |
- ET = essential thrombocythemia; MF = myelofibrosis; MPN = myeloproliferative neoplasm; MPN-SAF TSS = Myeloproliferative Neoplasm Symptom Assessment Form 10-item total symptom score; NA = not applicable; PV = polycythemia vera
-
aThis table summarizes only those symptoms included in the MPN-SAF 10-item instrument and is not inclusive of all symptoms that were assessed in the MPN Landmark survey. Symptom severity score was on a scale of 0 (absent) to 10 (worst imaginable); mean scores included in this table were calculated among those respondents who reported experiencing the symptom (ie, score ≥1) within the 12 months preceding the survey
-
bPresented as “fatigue” to respondents with MF and PV and as “fatigue and tiredness” to respondents with ET
-
cPresented as “night sweats” to respondents with MF and ET and as “day and night sweats” to respondents with PV
-
dDiffuse, not joint pain or arthritis
